1 / 48

Steven Vantine Educational Consultant State of California, Dept. of Public Health

Learn about the changes to the 2019 Immunization Schedule, including updates to Hepatitis A recommendations, pneumococcal vaccine updates, HPV vaccine, pertussis vaccination, and vaccine safety.

pcarson
Download Presentation

Steven Vantine Educational Consultant State of California, Dept. of Public Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ACIP Updates (June/October 2018) Steven Vantine Educational Consultant State of California, Dept. of Public Health Division of Communicable Disease Control Immunization Branch Version: 01.31.19RS

  2. Overview • 2019 Adult Immunization Schedule • 2019 Pediatric/Adolescent Immunization Schedule • Hepatitis A – New Recommendations • Pneumococcal vaccine updates • HPV Vaccine • Pertussis vaccination • Vaccine Safety: Shoulder Injury After Injection

  3. Disclosures Speaker has no financial conflict with manufacturers of any product named in this presentation. The use of trade names and commercial sources during this presentation is for identification only, and does not imply endorsement by the U.S. Department of Health and Human Services, the U.S. Public Health Service, the Centers for Disease Control and Prevention or the State of California, Immunization Branch.

  4. Objectives • Identify changes to the recommendations in the 2019 Immunization Schedule. • Identify changes to the ACIP Hepatitis A vaccination recommendations • Become knowledgeable about the proposed changes to the HPV age indications for vaccination • Discuss the possible changes to pertussis vaccination recommendations

  5. 2019 Immunization Schedule

  6. 2019 Immunization Schedule(s): • 2019 version became available on February 8th • No real changes to the actual immunization schedule • Some formatting changes • Utilization of ‘Tables’ to breakdown schedules at-a-glance • Transition from complete sentences to bullets • Removal of unnecessary or redundant language • Increase of font size for easier reading • Formatting changes • Remove unnecessary text while preserving all pertinent information and maintaining clarity https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html

  7. 2019 pediatric/adolescent Immunization schedule – vaccine list https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html

  8. 2019 pediatric/adolescent Immunization schedule https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html

  9. 2019 pediatric/adolescent Immunization schedule by medical condition https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html

  10. 2019 adult immunization schedule – Vaccine list https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pd

  11. 2019 adult immunization schedule https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pd

  12. 2019 adult immunization schedule by medical condition https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pd

  13. Hepatitis A Disease

  14. Hepatitis A Outbreaks – National https://www.cdc.gov/hepatitis/outbreaks/2017March-HepatitisA.htm

  15. Hepatitis A Person-to-Person Outbreak-Associated Cases, United States, August 1, 2016-June 18, 2018 California Other states with outbreaks of >100 cases *Linked epidemiologically and/or via viral sequencing to California cases

  16. Update on California Hepatitis A Outbreaks • With the slowdown in reported hepatitis A cases across California, CDPH has demobilized the outbreak response and continues to monitor reported hepatitis A cases statewide. • To date, San Diego and Santa Cruz have reported the greatest number of cases. • The majority of people who have been infected with hepatitis A virus in this outbreak are people experiencing homelessness and/or using illicit drugs in settings of limited sanitation.   • Other states are experiencing outbreaks in similar populations of at-risk people. • Intensive efforts by LHD’s and their clinical and community partners, the number of reported outbreak-associated cases has substantially decreased in California. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/Hepatitis-A-Outbreak.aspx

  17. ACIP Recommendations • The Advisory Committee on Immunization Practices (ACIP) recommends that the following persons be vaccinated against hep A: • All children at age 1 year, • Persons who are at increased risk for infection, • Persons who are at increased risk for complications from hepatitis A, and • Any person wishing to obtain immunity (protection). https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/hepatitis-04-nelson.pdf

  18. ACIP Recommendations (cont.): • Persons at increased risk for Hepatitis A infection: • Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A.  • Men who have sex with men • Users of injection and non-injection drugs. • Persons who have occupational risk for infection • Persons who have chronic liver disease • Household members and other close personal contacts of adopted children newly arriving from countries with high or intermediate hepatitis A endemicity. • Persons with direct contact with persons who have hepatitis A https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine

  19. ACIP Recommendations (cont.): • Hepatitis A vaccines should be administered for post-exposure prophylaxis for all persons aged ≥12 months. • In addition to hepatitis A vaccine, immune globulin may be administered to persons aged >40 years depending on the providers’ risk assessment. • Hepatitis A vaccine should be administered to infants aged 6-11 months traveling outside the United States when protection against hepatitis A is recommended. • October 2018 ACIP - All persons aged 1 year and older experiencing homelessness should be routinely immunized against hepatitis A https://www.cdc.gov/vaccines/acip/hepatitis_A

  20. Dosage and Schedules for Hepatitis A Vaccine https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine

  21. Dosage and Schedules for Hepatitis A Vaccine https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine

  22. Human Papilloma Virus

  23. How do people get HPV? • HPV is transmitted through intimate skin-to-skin contact. • You can get HPV by having vaginal, anal, or oral sex with someone who has the virus. • It is most commonly spread during vaginal or anal sex. • HPV is so common that nearly all men and women get it at some point in their lives.

  24. How do people get HPV? • HPV can be passed even when an infected person has no signs or symptoms. • You can develop symptoms years after being infected, making it hard to know when you first became infected. • In most cases, HPV goes away on its own and does not cause any health problems. • When HPV does not go away, it can cause health problems like genital warts and cancer.

  25. Disease Burden of HPV-Associated Cancers

  26. HPV Disease Burden (US data, 2010-2014) https://www.cdc.gov/cancer/hpv/statistics/cases.htm

  27. HPV Vaccines: • The vaccine first became available in June of 2006 • HPV vaccines are highly immunogenic. • All HPV vaccines have been found to have high efficacy (close to 100%) for prevention of HPV  • Quadrivalent vaccine was also found to have high efficacy (99%) for prevention of genital warts.  • Quadrivalent vaccine also demonstrated high efficacy was also in among men who have sex with men (MSM). • Prior infection with one HPV vaccine type did not diminish efficacy of vaccine against the other HPV vaccine types https://www.cdc.gov/vaccines/vpd/hpv/hcp/vaccines.html

  28. ACIP HPV Vaccine Recommendations • Routine HPV vaccination at 11-12 years • As early as 9 years (Recommended for children with history of sexual abuse or assault.) • Females 13-26 years and males 13-21 years if not adequately vaccinated previously • Males 22-26 years may be vaccinated • Men who have sex with men*, transgender persons, or immunocompromised persons (including those with HIV) 22-26 years if not adequately vaccinated *Including men who identify as gay or bisexual, or who intend to have sex with men. http://www.cdc.gov/mmwr/pdf/wk/mm6411.pdf

  29. HPV Vaccine Recommendations 1 In a 2-dose schedule of HPV vaccine, the minimum interval is 5 months between the 1st and 2nd dose. 2 Persons with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity. 3 In a 3-dose schedule, the minimum interval between the 1st and 2nd dose is 4 weeks, 12 weeks between the 2nd and 3rd dose, and 5 months between the 1st and 3rd dose.

  30. Reminder: Other Guidance • 9vHPV vaccine may be used to continue or complete a series started with another HPV vaccine. • If the series is interrupted, the series does not need to be restarted. • Number of doses based on age at initiation of series. http://www.cdc.gov/mmwr/pdf/wk/mm6411.pdf

  31. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-04-Markowitz-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-04-Markowitz-508.pdf

  32. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-04-Markowitz-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-04-Markowitz-508.pdf

  33. Harmonization of HPV Schedules: • February 2018 ACIP discussion: harmonize schedules • Would simplify immunization schedule • Might facilitate reaching males, including high risk males • Preliminary data suggests male HPV vaccination rates are lower in males than in females • Studies being conducted to determine the benefit of harmonizing schedules https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-04-Markowitz-508.pdf

  34. Harmonization of HPV Schedules: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-04-Markowitz-508.pdf

  35. Harmonization of HPV Schedules: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/HPV-04-Markowitz-508.pdf

  36. Second Dose Pertussis Vaccine

  37. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  38. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  39. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  40. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  41. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  42. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  43. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  44. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  45. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  46. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdfhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-10/Pertussis-02-Havers-508.pdf

  47. Questions?

  48. Steven J. VanTine Educational Consultant, Immunization BranchDivision of Communicable Disease Control, Center for Infectious DiseasesCalifornia Department of Public HealthOffice: 510.412.1593Email:steven.vantine@cdph.ca.gov

More Related